Researchers from Kyushu University have identified a potential therapeutic target for the treatment of advanced multiple sclerosis (MS), a potentially disabling condition associated with the central ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib, delayed ...

Researchers from Kyushu University have identified a potential therapeutic target for the treatment of advanced multiple sclerosis (MS), a potentially disabling condition associated with the central ...

Multiple sclerosis is especially destructive because of its tendency to worsen progressively. Instead of working through the immune system, Quantum BioPharma’s Lucid-MS acts directly on the myelin ...

Advanced Neurology of Colorado (ANC) will officially celebrate the opening of its new comprehensive multiple sclerosis center ...

(Reuters) -Sanofi's most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease, but in a positive surprise succeeded in a ...

Scientists have uncovered a surprising clue that may help explain why multiple sclerosis (MS) progresses rapidly in some people but not others. In brain tissue from patients with severe MS, ...

Differences in the complexity of the EEG signal (yellow and red colors) in a specific brain area between the group with advanced multiple sclerosis and the control group, and multifractal spectra ...

While recent therapies have the potential to stall or delay the progression of multiple sclerosis, a new study shows that young Black and Hispanic women fare worse than young white women. Minority ...

Multiple sclerosis is characterised by central nervous system inflammation and demyelination, which lead to neurodegeneration and impaired neural drive to skeletal muscle. As a result, individuals ...

SAN DIEGO--(BUSINESS WIRE)--SEQSTER PDM Inc. (“SEQSTER”), the leading patient-centric healthcare technology company, has been selected by the Multiple Sclerosis Association of America (MSAA) for its ...

The astroglia (a class of neural cells) of patients with MS overproduce a channel protein known as connexin 43. This overproduction facilitates the release of pro-inflammatory chemicals that trigger a ...